INIMMUNE CORP — Department of Health and Human Services SBIR Phase II: 91
INIMMUNE CORP — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,836,453
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 91
- Solicitation
- PHS2021-1
- NAICS
- —
- Place of performance
- MT
- Period
- —
Description
The goal of this project is to develop an intranasal TLR4 agonist to treat allergic rhinitis. Such treatment has the potential to provide short-term symptom control as well as long-term disease remission via allergen dependent T and B cell memory responses.